The Gut-Brain Axis: How Your Microbiome Holds the Key to Mental Health

Introduction: The gut-brain axis

The gut-brain axis is a two-way communication network between the digestive system and the brain, involving hormones, metabolism, the immune system, and other pathways. Key components include the autonomic nervous system, the hypothalamic-pituitary-adrenal (HPA) axis, and gut nerves that link the brain to digestion and immune responses. The gut can also influence mood, cognition, and mental health (Appleton, 2018).

Gut bacteria play a crucial role in this relationship, affecting mental health, emotional regulation, and the HPA axis. Changes in the gut microbiome have been linked to mood disorders like anxiety and depression, as well as gastrointestinal (GI) diseases like irritable bowel syndrome, which often coincide with psychological conditions. Gut microbiota also impact brain development in fetuses and newborns, and diet influences how the gut microbiome affects cognitive functions (Appleton, 2018).

Depression

Depression is a mood disorder characterized by feelings of sadness, emptiness, or irritability, leading to a loss of interest in daily activities. It can cause both mental and physical changes that interfere with everyday life. In the U.S., depression contributes to nearly 40,000 suicides each year, with older men being at the highest risk (Chand & Arif, 2023). Depression can affect anyone, regardless of age or social background, impacting both women and men. If symptoms persist for more than two weeks, it may indicate depression (InformedHealth.org, 2020).

Major Depressive Disorder (MDD) has multiple causes, including biological, genetic, environmental, and psychological factors. While it was initially thought to be due to imbalances in neurotransmitters like serotonin, norepinephrine, and dopamine, newer research suggests disruptions in complex neural circuits. Other neurotransmitters, such as GABA and glutamate, as well as hormonal imbalances, also play a role. Early life stress and trauma can result in lasting brain changes that contribute to depression. Genetics have a strong influence, especially in twins, and life events, personality traits, and cognitive distortions further increase the risk (Chand & Arif, 2023).

Diagnosis of major depression is primarily made through a clinical evaluation, including a detailed interview and mental status examination, and is found to be as reliable as many medical tests (Goldman et al., 1999). The DSM-5 provides specific criteria for diagnosing depression (Regier et al., 2013).

Treatment typically involves medication and brief psychotherapy, such as cognitive-behavioral therapy (CBT) or interpersonal therapy. Combining these treatments improves symptom relief and quality of life. CBT is particularly effective in preventing relapse. Despite effective treatments, about 50% of people may not initially respond, and full recovery is uncommon. However, around 40% of patients experience partial improvement within a year (Chand & Arif, 2023).

Selective Serotonin Reuptake Inhibitors (SSRIs)

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for treating depression. They are usually the first choice for pharmacotherapy because of their safety, effectiveness, and good tolerance in both adults and children (Chu & Wadhwa, 2023). 

SSRIs work by increasing the levels of serotonin, also known as 5-hydroxytryptamine (5-HT), in the brain, which is often low in individuals with depression. They do this by blocking the serotonin transporter (SERT) at nerve endings, which prevents the reabsorption (reuptake) of serotonin. This action keeps more serotonin in the brain's synapses, allowing it to have a more prolonged effect on mood (Figure 1). Unlike other antidepressants, SSRIs primarily target serotonin and have minimal impact on other neurotransmitters like dopamine or norepinephrine (Chu & Wadhwa, 2023).

Figure 1: A schematic diagram illustrating the mechanism of SSRIs: These medications block the reuptake of serotonin at the presynaptic membrane, leading to increased serotonin levels at the postsynaptic nerve terminal membrane. Image taken from (Lattimore et al., 2005).

Serotonin is also present in the gut mainly at the enterochromaffin (EC) cells of the mucosa. It interacts with various receptors in the gut, the 5-HT3 and 5-HT4 receptors have been most extensively studied for their role in gut motility. It has also been seen that, 5-HT released from EC cells is capable of inducing the mucosal peristaltic reflex and hence propulsive peristalsis (Kendig & Grider, 2015).

5-HT synthesis and gut-brain interaction

As mentioned above, serotonin (5-HT) in the gut is produced from tryptophan in enterochromaffin (EC) cells and serotonergic neurons through the actions of tryptophan hydroxylase 1 and 2 (TPH1 and TPH2), converting tryptophan into 5-hydroxytryptophan (5-HTP), which is then turned into serotonin by L-amino acid decarboxylase (L-AADC). This serotonin, along with chromogranin A (CGA), is stored in vesicles via vesicular monoamine transporter 1 (VMAT1). EC cells release serotonin into the extracellular space in response to various stimuli, including chemical and mechanical changes. Most serotonin is released into the extracellular space, with an amount going into the gut lumen. Serotonin is taken up by surrounding enterocytes via the serotonin reuptake transporter (SERT) and then metabolized into 5-hydroxyindoleacetic acid (5-HIAA) by monoamine oxidase (MAO). In serotonergic neurons, serotonin is released into the synaptic cleft, where it acts on postsynaptic receptors and is reabsorbed by SERT. Serotonin is also taken up by endothelial cells and platelets, where it is either converted into 5-HIAA or transported to other tissues (Figure 2) (Liu et al., 2021).

Figure 2: Schematic representation of 5-HT biosynthesis and metabolism. Image taken from (Liu et al., 2021).

The brain-gut hypothesis suggests that serotonin (5-HT) plays a key role in the communication between the gut and the brain. While most serotonin is found in the gut, it also influences brain functions like mood, sleep, and appetite. Imbalances in serotonin levels or receptor activity can result in gastrointestinal issues, such as irritable bowel syndrome (IBS), as well as symptoms in other parts of the body. Research indicates that therapies targeting serotonin can help manage IBS symptoms and related central nervous system dysfunctions (Crowell & Wessinger, 2007).

A study investigating the effects of selective serotonin reuptake inhibitors (SSRIs) and the probiotic Lactobacillus rhamnosus JB-1 on gut-brain signaling through the vagus nerve found some interesting results. Using mouse models, researchers observed that oral SSRI treatment activated vagal pathways, which were crucial for reducing anxiety and depression-like behaviors. Similarly, Lactobacillus rhamnosus JB-1 alleviated these behaviors, but its effectiveness was reduced in mice with a severed vagus nerve. This highlights the importance of vagal signaling in gut-brain communication. Both SSRIs and the probiotic also affected the gut microbiota and serotonin levels, suggesting the potential of targeting the gut-brain axis in treating mood disorders like anxiety and depression (McVey et al., 2019).

Comprehensive review: Depressive gut microbiota

Depressive Gut Microbiota refers to an imbalanced composition and reduced diversity of microorganisms in the gastrointestinal tract, which has been connected to the development and progression of depression. 

Studies have shown that individuals with depression exhibit differences in the microbiota community across various taxonomic levels when compared to those without depression, including variations in both α-diversity and β-diversity. At the phylum level, there were inconsistencies in the abundance of Firmicutes, Bacteroidetes, and Proteobacteria, but higher levels of Actinobacteria and Fusobacteria were consistently observed in depressed individuals. On the family level, people with depression had increased levels of families like Actinomycineae, Bifidobacteriaceae, Clostridiaceae, and Streptococcaceae, while families such as Veillonellaceae and Prevotellaceae were less abundant. At the genus level, those with depression showed higher levels of genera like Oscillibacter, Blautia, Streptococcus, and Klebsiella, with lower levels of beneficial bacteria like Coprococcus, Lactobacillus, and Escherichia/Shigella. These changes in gut microbiota composition are evident in those living with depression, and they are associated with inflammation, gut barrier dysfunction, and disruption of gut-brain communication, contributing to depressive symptoms (Barandouzi et al., 2020).

Study 1: Gut Microbiome Patterns Associated With Treatment Response in Patients With Major Depressive Disorder (Bharwani et al., 2020)

The first long-term study to explore a potential link between major depressive disorder (MDD) and the gut microbiome by analyzing microbial patterns before starting antidepressant treatment and during 6 months of therapy. No other research has looked at the microbiota in individuals who have not yet begun antidepressant use (Bharwani et al., 2020).

Results: Microbial differences

Fifteen participants (average age 36.9, SD = 12.9; 12 women) were studied. At the start, their average Montgomery–Åsberg Depression Rating Scale (MADRS) score was 22.53 (SD = 6.63). After 6 months, 11 participants were classified as "remitters" (MADRS < 12) and 4 as "nonremitters" (MADRS > 13). Most participants took Escitalopram, while a few took Citalopram (Bharwani et al., 2020).

Baseline diversity of gut microbiota was higher in remitters than in nonremitters (Figure 3). However, there were no differences in variability or community clustering based on treatment response. At baseline, 22 gut microbiota types of operational taxonomic units (OTUs) were different between the two groups. No significant changes in diversity were observed at 3 months, but differences reappeared at 6 months. Within-subject diversity and community composition showed no significant changes over time for either group (Bharwani et al., 2020).

One OTU, a Clostridiales, increased in remitters at 6 months, while no OTUs changed in nonremitters. At 3 months, 35 OTUs were different between the groups, and by 6 months, 42 OTUs showed differences, with some also differing at 3 months. Diet and antidepressant type had no impact on these results (Bharwani et al., 2020).

Figure 3: Baseline differences between eventual responders and nonresponders in alpha-diversity metrics. Image taken from (Bharwani et al., 2020).

Conclusion

The study shows that antidepressant treatment impacts the microbiota at the OTU level, based on how well patients respond to treatment. Although overall diversity and microbiota profiles did not change significantly in either group, remitters continued to have higher diversity compared to nonremitters after 6 months. This indicates a potential microbial community signature that differentiates between treatment responders and nonresponders (Bharwani et al., 2020).

Study 2: Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression (Zheng et al., 2020)

Gut microbiome changes are linked to major depressive disorder (MDD) and bipolar disorder (BD), but their specific differences are unclear. This study identifies unique microbial patterns for MDD and BD and offers markers to differentiate between the two based on gut microbiome signatures (Zheng et al., 2020).

Results: Distinct gut microbiome signature in MDD and BD

The study compared gut microbiomes across individuals with bipolar disorder (BD), major depressive disorder (MDD), and healthy controls (HC). At the phylum level (Figure 4a), BD had lower Bacteroidetes and higher Proteobacteria compared to MDD and HC. At the family level (Figure 4b), BD showed elevated Pseudomonadaceae, while MDD had higher Bacteroidaceae and Bifidobacteriaceae but lower Enterobacteriaceae than HC. Comparing BD and MDD, BD had more Enterobacteriaceae and Pseudomonadaceae, while MDD showed higher Bacteroidaceae and Veillonellaceae (Zheng et al., 2020).

Figure 4: (a) At the phylum level. (b) At the family level. Image taken from (Zheng et al., 2020).

Results: Gut Microbial Biomarkers for Discriminating MDD, BD, and HC 

They identified four microbial OTUs, mostly from the Lachnospiraceae family, that were strongly linked to Hamilton Depression Rating Scale (HAMD) scores in MDD and BD patients (Figure 5). These microbial markers helped distinguish between MDD, BD, and healthy controls and also indicated the severity of MDD or BD in patients (Zheng et al., 2020).

Figure 5: Four microbial OTUs, primarily from the Lachnospiraceae family, showed significant links to HAMD scores in MDD and BD patients. Red lines represent positive correlations, while blue lines represent negative correlations, with thicker lines indicating stronger statistical significance (p < 0.05). Image taken from (Zheng et al., 2020).

Conclusion

In summary, they identified distinct gut microbiota differences between MDD, BD, and healthy controls. The researchers also found markers that effectively distinguishes MDD from BD and HC. 

Looking at all these studies, they confirm that there is a connection between the gut and the brain.

Role of the Vagus Nerve

The vagus nerve is a key part of the parasympathetic nervous system, responsible for regulating essential functions like mood, immune response, digestion, and heart rate. It serves as a communication link between the brain and the gastrointestinal tract, transmitting information about the condition of internal organs to the brain through afferent fibers (Breit et al., 2018).

Issues with the vagus nerve or changes in its function have been linked to a range of gastrointestinal and psychiatric disorders (Breit et al., 2018).

Importance of Vagus Nerve

A study demonstrated that the vagus nerve impacts the anxiety-reducing effects of Lactobacillus rhamnosus by acting as a conduit for communication between the gut microbiota and the brain. The study shows that when the vagus nerve is severed, the beneficial effects of L. rhamnosus on anxiety and behavior are lost, indicating that the vagus nerve is essential for transmitting signals from the gut microbiota to the brain. This underscores the nerve’s crucial role in modulating the gut-brain axis, affecting how gut microbiota influence mental health and stress responses (Bravo et al., 2011).

BDNF (Brain-derived neurotrophic factor)

BDNF is a protein essential for the growth, maintenance, and survival of neurons in the brain, especially in regions such as the hippocampus, which are critical for memory, learning, and mood regulation. Changes in gut microbiota composition may affect BDNF levels, thereby influencing cognitive functions and neuroplasticity. This underscores the bidirectional relationship between the gut and brain (Agnihotri & Mohajeri, 2022).

Lactobacillus in digestive system

(Capuco et al., 2020)

A study found that patients with major depressive disorder (MDD) who took SSRIs along with the probiotic Lactobacillus plantarum 299v had significantly lower levels of kynurenine, a neurotoxic compound linked to cognitive decline and mood disorders. This group also showed improved cognitive functions, including better attention, perception, and verbal learning, compared to a placebo group. Kynurenine, which can harm the central nervous system, is produced during inflammation triggered by the immune system. The probiotic may have reduced intestinal inflammation, leading to lower kynurenine production and contributing to improved cognition and mood (Capuco et al., 2020).

(Han & Kim, 2019)

This study found that isolated Lactobacillus mucosae NK41 and Bifidobacterium longum NK46, derived from human feces, increased levels of brain-derived neurotrophic factor (BDNF) in cells stressed with corticosterone. In mice, both probiotics, alone and in combination, reduced anxiety and depression related to stress, lowered inflammation and stress markers in the brain and blood, and improved gut health. They also decreased populations of Proteobacteria and Bacteroidetes in the gut, as well as bacterial lipopolysaccharide production. These findings suggest that these probiotics may alleviate anxiety, depression, and colitis by mitigating gut dysbiosis (Han & Kim, 2019).

(Yong et al., 2020)

Lactobacillus rhamnosus, has shown antidepressant effects in both healthy and stressed mice. Studies in postpartum women and obese individuals also reported reduced depressive thoughts with its use. Its positive effects are linked to signaling through the vagus nerve, influencing brain activity and the stress-regulating hypothalamic-pituitary-adrenal (HPA) axis. L. rhamnosus produces Gamma-aminobutyric acid (GABA), a neurotransmitter that helps regulate mood, and can cross the gut barrier to interact with neurons. This probiotic also lowers stress hormones and may help prevent depression by boosting GABA levels and protecting against HPA axis overactivity (Yong et al., 2020).

These studies demonstrate that a specific Lactobacillus strain effectively treats major depressive disorder (MDD) by lowering inflammation and increasing serotonin production.

Strength and limitations

Strengths

Clinical Relevance: Understanding the gut-brain axis has key clinical implications for treating various conditions, including mental health disorders like depression, anxiety, and irritable bowel syndrome (IBS), as well as neurological diseases like Parkinson’s and Alzheimer’s.

Therapeutic Potential: Research on the gut-brain axis has led to innovative treatments targeting gut microbiota, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), offering potential for managing gastrointestinal and psychiatric disorders.

Advanced Technologies: Cutting-edge tools such as metagenomics, metabolomics, and neuroimaging have enhanced the study of the gut-brain axis, helping researchers uncover the mechanisms of gut-brain communication with greater precision.

Limitations

Correlational Nature: Much of the research is based on associations between gut microbiota and brain function or behavior, making it difficult to establish causality and deeper understanding.

Animal Models: Many gut-brain axis studies use animal models, which may not fully reflect human physiology and behavior. Translating these findings to humans requires careful attention to species differences and limitations.

Long-term Effects and Safety: The long-term safety and effects of gut microbiota-targeted interventions for mental health are still unclear. More research is needed to evaluate potential risks and benefits over extended periods.

Implications and Applications

Probiotic Supplements: Recommending probiotics with beneficial bacteria to help balance gut microbiota.

Psychotherapy: Using therapies like cognitive-behavioral therapy (CBT) that address both mental health and gut-brain axis interactions.

Medication: Considering medications that influence the gut-brain axis, including specific antidepressants or treatments targeting gut microbial imbalances.

Education and Awareness: Informing patients about the link between gut health and mental well-being to help them make better lifestyle choices.

Related Research and Future Directions

Role in Neurological and Psychiatric Disorders: Exploring the influence of the gut-brain axis on a variety of neurological and psychiatric conditions beyond depression and anxiety, such as Alzheimer's, Parkinson's, autism spectrum disorders, schizophrenia, and bipolar disorder. This research could reveal common underlying mechanisms and highlight new therapeutic options.

Gut Microbiota and Brain Development: Examining how gut microbiota impacts brain development and function during key stages like infancy, childhood, and adolescence. Insights into early microbial exposures could guide strategies for enhancing neurodevelopment and brain health.

Technological Advances: Utilizing cutting-edge tools like microbiome sequencing, multi-omics profiling, neuroimaging, and computational modeling to delve deeper into gut-brain interactions. Combining diverse data sources will allow for more detailed analyses of complex biological systems.

Conclusion

With the growing pressures of modern life, depression has become increasingly prevalent, yet a complete cure remains unknown. Research on the gut-brain axis suggests a strong connection between depression and changes in the gut microbiota. Depression can disrupt the gut's microbial balance and potentially trigger complications like IBS. IBS, linked to gut microbiota imbalance, also increases the risk of depression. Adjusting and restoring the gut microbiota composition may help alleviate depressive symptoms. This highlights the importance of investigating microbiota-based treatments for depression (Zhu et al., 2022).

References

Agnihotri N, Mohajeri MH. Involvement of Intestinal Microbiota in Adult Neurogenesis and 

the Expression of Brain-Derived Neurotrophic Factor. Int J Mol Sci. 2022 Dec 14;23(24):15934. doi: 10.3390/ijms232415934. PMID: 36555576; PMCID: PMC9783874.

Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integr 

Med (Encinitas). 2018 Aug;17(4):28-32. PMID: 31043907; PMCID: PMC6469458.

Barandouzi ZA, Starkweather AR, Henderson WA, Gyamfi A, Cong XS. Altered Composition 

of Gut Microbiota in Depression: A Systematic Review. Front Psychiatry. 2020 Jun 10;11:541. doi: 10.3389/fpsyt.2020.00541. PMID: 32587537; PMCID: PMC7299157.

Bharwani A, Bala A, Surette M, Bienenstock J, Vigod SN, Taylor VH. Gut Microbiome 

Patterns Associated With Treatment Response in Patients With Major Depressive Disorder. Can J Psychiatry. 2020 Apr;65(4):278-280. doi: 10.1177/0706743719900464. Epub 2020 Jan 21. PMID: 31958990; PMCID: PMC7385422.

Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, 

Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5. doi: 10.1073/pnas.1102999108. Epub 2011 Aug 29. PMID: 21876150; PMCID: PMC3179073.

Breit S, Kupferberg A, Rogler G, Hasler G. Vagus Nerve as Modulator of the Brain-Gut Axis 

in Psychiatric and Inflammatory Disorders. Front Psychiatry. 2018 Mar 13;9:44. doi: 10.3389/fpsyt.2018.00044. PMID: 29593576; PMCID: PMC5859128.

Capuco A, Urits I, Hasoon J, Chun R, Gerald B, Wang JK, Kassem H, Ngo AL, Abd-Elsayed 

A, Simopoulos T, Kaye AD, Viswanath O. Current Perspectives on Gut Microbiome Dysbiosis and Depression. Adv Ther. 2020 Apr;37(4):1328-1346. doi: 10.1007/s12325-020-01272-7. Epub 2020 Mar 4. PMID: 32130662; PMCID: PMC7140737.

Chand SP, Arif H. Depression. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure 

Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430847/

Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. [Updated 2023 May 1]. In: 

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554406/

Crowell MD, Wessinger SB. 5-HT and the brain-gut axis: opportunities for pharmacologic 

intervention. Expert Opin Investig Drugs. 2007 Jun;16(6):761-5. doi: 10.1517/13543784.16.6.761. PMID: 17501688.

Goldman LS, Nielsen NH, Champion HC. Awareness, diagnosis, and treatment of 

depression. J Gen Intern Med. 1999 Sep;14(9):569-80. doi: 10.1046/j.1525-1497.1999.03478.x. PMID: 10491249; PMCID: PMC1496741.

Han SK, Kim DH. Lactobacillus mucosae and Bifidobacterium longum Synergistically 

Alleviate Immobilization Stress-Induced Anxiety/Depression in Mice by Suppressing Gut Dysbiosis. J Microbiol Biotechnol. 2019 Sep 28;29(9):1369-1374. doi: 10.4014/jmb.1907.07044. PMID: 31564078.

InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in 

Health Care (IQWiG); 2006-. Depression: Learn More – Treatments for depression. [Updated 2020 Jun 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279282/

Kendig DM, Grider JR. Serotonin and colonic motility. Neurogastroenterol Motil. 2015 

Jul;27(7):899-905. doi: 10.1111/nmo.12617. PMID: 26095115; PMCID: PMC4477275.

Lattimore, Keri & Donn, Steven & Kaciroti, Niko & Kemper, Alex & Neal, Charles & Vázquez, 

Delia. (2005). Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. Journal of perinatology : official journal of the California Perinatal Association. 25. 595-604. 10.1038/sj.jp.7211352. 

Liu N, Sun S, Wang P, Sun Y, Hu Q, Wang X. The Mechanism of Secretion and Metabolism 

of Gut-Derived 5-Hydroxytryptamine. Int J Mol Sci. 2021 Jul 25;22(15):7931. doi: 10.3390/ijms22157931. PMID: 34360695; PMCID: PMC8347425.

McVey Neufeld, KA., Bienenstock, J., Bharwani, A. et al. Oral selective serotonin reuptake 

inhibitors activate vagus nerve dependent gut-brain signalling. Sci Rep 9, 14290 (2019). https://doi.org/10.1038/s41598-019-50807-8

Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World 

Psychiatry. 2013 Jun;12(2):92-8. doi: 10.1002/wps.20050. PMID: 23737408; PMCID: PMC3683251.

Yong SJ, Tong T, Chew J, Lim WL. Antidepressive Mechanisms of Probiotics and Their 

Therapeutic Potential. Front Neurosci. 2020 Jan 14;13:1361. doi: 10.3389/fnins.2019.01361. PMID: 32009871; PMCID: PMC6971226.

Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, Tan X, Huang Y, Chai T, Zhang H, Duan J, 

Zhou J, Sun Z, Chen X, Marwari S, Lai J, Huang T, Du Y, Zhang P, Perry SW, Wong ML, Licinio J, Hu S, Xie P, Wang G. Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Adv Sci (Weinh). 2020 Feb 5;7(7):1902862. doi: 10.1002/advs.201902862. PMID: 32274300; PMCID: PMC7140990.

Zhu F, Tu H, Chen T. The Microbiota-Gut-Brain Axis in Depression: The Potential 

Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect. Nutrients. 2022 May 16;14(10):2081. doi: 10.3390/nu14102081. PMID: 35631224; PMCID: PMC9144102.